

22. Mitteilungsblatt

Nr. 25

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2023/2024
22. Stück; Nr. 25

Bevollmächtigungen

25. Bevollmächtigungen gem. § 27 Abs. 2 UG

25. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitle	Organisationseinheit	Projektleiter(in)
FA731B0212	Neoadjuvant CHEmoradiotherapy with sequential Ipilimumab and Nivolumab in REctal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial	Allgemeinchirurgie_7 31	Längle Johannes
FA731B2403	Validation of the Xpert(R) Insight Breast Cancer test to stratify outcomes in Premenopausal Woman with Hormone receptor positive (HR+) , HR2-negative early breastcancer and Evaluation of the Concordance of Xpert(R) Breast Cancer with IHC assessment of routine breast cancer biomarkers (ER, PgR, HER2 and Ki7) - a retrospective translational study of biomarker cohort ABCSG-12 (TraX&Violds-03)	Allgemeinchirurgie_7 31	Exner Ruth
FA731B2404	CAMBRIS-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestran8 (AZD9833), versus Standard Endocrine Therapy	Allgemeinchirurgie_7 31	Exner Ruth
FA731B2501	Development and Evaluation of Cancer Immune Therapies with Malignant Ascites from Ovarian and Pancreatic Cancer	Allgemeinchirurgie_7 31	Pils Dietmar
FA731E0211	Cell therapy approaches for allergy prevention	Allgemeinchirurgie_7 31	Wekerle Thomas
FA731E0212	Observational Study on the Clinical Use of EVUSHELD (AZD7442) in Austria	Allgemeinchirurgie_7 31	Wekerle Thomas
FA731E0213	ECP induction therapy after lung transplantation -- Horizon-MSCA-2022-DN-01(EU Projekt exTRA 101119855)	Allgemeinchirurgie_7 31	Wekerle Thomas

FA731X0301	Investigating the role of the immune response in shaping fibroblast activation and recurrence in Crohn's disease	Allgemeinchirurgie_731	Unger Lukas
FA738A0407	PeriOperative ISchemic Evaluation 3	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Fleischmann Edith
FA738A0807	ICU4Covid - Number101016000	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A0812	Ärzte Ausbildung 4.0	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A0813	Quantitative and Qualitative Assessment of the Small Sized Physiological Patient Monitor (SSPPM): Clinical Test 1C	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A0816	Multi-center, prospective, open label, single arm post-market study of BD NRFit™ Spinal Needles, NRFit™ Spinal Introducer Needles, and NRFit™ Syringe on participants who are receiving a neuraxial procedure	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A0817	Improving patient outcomes and reducing cognitive load of clinical staff in intensive care through medical- device interoperability and an open and secure IT ecosystem	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A0903	BioMembrOS	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Claus
FA738A1304	Prospektive, randomisierte Studie zur Personalisierten Medizin mit Pentaglobin nach einer interventionellen Fokussanierung bei Peritonitis-Patienten	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA738A1602	Treatment of anemia with intravenous iron in patients listed for orthotopic liver transplantation	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Baron David
FA738A1902	Implementation of a remote general ward monitoring workflow for high-risk surgical patients after	Anästhesie, Allgemeine	Willschke Harald

	discharge from the ICU: A Non-Comparative Prospective Pilot Study with A Historical Control.	Intensivmedizin und Schmerztherapie_738	
FA738A2403	Eine retrospektive Studie an Patientendaten zur Bewertung der klinischen Praxis, Behandlungsmuster und Ergebnisse von 4-Faktor-Prothrombinkomplex-Konzentraten (PPSB) bei mit Faktor-Xa(FXa)-Inhibitoren behandelten Patienten vor einer Operation oder einem invasiven Eingriff bzw. bei solchen mit erforderlicher Wirkungsumkehr bei schweren Blutungen	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Gratz Johannes
FA738A2703	An Investigational Study to evaluate the safety and performance of the BD PosiFlush™ SafeScrub on needleless access devices.	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Windpassinger Marita
FA738C0702	Eine prospektive, randomisierte, doppelblinde, Placebo kontrollierte Studie zur Evaluierung von Landiololhydrochlorid in der Prävention von Vorhofflimmern bei Patienten mit Herzoperation	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Steinlechner Barbara
UE73806005	Osteoarthritis and Pain	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Weigl Lukas
FA746A0267	YOSEMITE: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0268	RHINE: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula

FA746A0268	RHINE: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0268	RHINE: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0268	RHINE: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0269	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (LUCERNE)	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0270	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA)	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0270	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula

	MACULAR DEGENERATION (TENAYA)		
FA746A0271	Collaborative Award: Deciphering AMD by deep phenotyping and machine learning (PINNACLE)	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0272	A 64-week, two-arm, random., double-masked, multicenter, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg comp. to aflibercept 2 mg in a treat-to-control regimen in patients with nAMD	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0278	GLEAM & GLIMMER: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME); BEACON: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO); GLOW: A Phase 3, Prospective, Randomized, Double-masked, Sham Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Participants with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR)	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0281	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula

	MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION		
FA746A0288	Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0289	I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0320	General Research Funding - Funding Agreement	Augenheilkunde und Optometrie_746	Pieh Stefan
FA746A1632	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1637	A phase IIIb, global, multicenter, randomized, visual assessor-masked study of the efficacy, safety, and pharmacokinetics of a 36-week refill regimen for the port delivery system with Ranibizumab in patients with neovascular age-related macular degeneration	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1650	An open-label extension (OLE) phase 3 trial to assess the safety of intravitreal administration of avacincaptad pegol (complement C5 inhibitor) in patients with geographic atrophy who previously completed phase 3 study ISEE2008	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1652	Influence of Fluid Fluctuation on the Development of Fibrosis and Atrophy in nAMD under Intravitreal Faricimab Treatment mit dem zugelassenen Arzneimittel Vabysmo® (Faricimab)	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan

FA746A1653	A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A2605	A Non-interventional Multi-center Study Evaluating Clinical Treatment with Idebenone in Patients with Chronic Leber's Hereditary Optic Neuropathy (LHON)	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A3110	Rotation the hydrophobic acrylic Vivinex Impress intraocular lens	Augenheilkunde und Optometrie_746	Leydolt Christina
FA746A3601	Annotation Service Agreement	Augenheilkunde und Optometrie_746	Reiter Gregor Sebastian
FA746A3702	Visual performance of the AcrySof Vivity hydrophobic intraocular lens (IOL) in patients with mild irregular astigmatism	Augenheilkunde und Optometrie_746	Schartmüller Daniel
FA746A1651	A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA662A1101	Entwicklung und Charakterisierung von 3D-druckbare leitfähige Bio-Nanokomposite	Biomedizinische Forschung und Translationale Chirurgie_308	Enayati Marjan
FA662A0403	MG-Mitralring	Biomedizinische Forschung_308	Podesser Bruno Karl
FA662A0406	Octapharma AG - Appendix A	Biomedizinische Forschung_308	Podesser Bruno Karl
FA727A0609	Phase I, open Label, multicenter, dose escalation 2055/20and DLBCL	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina
FA727A0614	Phase Ib Open Label Multi Center, Dose Escalation and Expansion Study of APN401 in Patients with Advanced Solid Tumors	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina

FA695A0101	The HIGH (Resolution) WAY To Cells - a platform for high resolution single cell omics	Core Facilities_2012	Wojta Johann
FA722A0508	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy.	Dermatologie_722	Jonak Constanze
FA722A0509	A multicenter, prospective observational, non-interventional, multinational (Austria, Switzerland, Czech Republic) study to assess the effectiveness and safety of Tildrakizumab in the treatment of genital psoriasis CzATCH Study	Dermatologie_722	Jonak Constanze
FA722A0510	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa	Dermatologie_722	Jonak Constanze
FA722A0511	Randomisierte, doppelblinde, placebokontrollierte Studie der Phase IIb/Phase III zur Beurteilung der Wirksamkeit und Sicherheit von Spesolimab bei Patienten mit mittelschwerer bis schwerer Hidradenitis suppurativa. Lunsayil 1.	Dermatologie_722	Jonak Constanze
FA722A0702	Eine epidemiologische, pathogenetische und immunologische Untersuchung der interstitiellen Lungenerkrankung in einer Gruppe von Patienten mit Plaque-Psoriasis oder Psoriasis-Arthritis	Dermatologie_722	Heil Peter
FA722B1121	CA224-020 - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal antibody (BMS-986016) Administered Alone and in Combination with Anti-PD1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.	Dermatologie_722	Höller Christoph

FA722B1143	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Dermatologie_722	Höller Christoph
FA722C0437	A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bicitgravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)" (MK-8591A-018-Site number 3402)	Dermatologie_722	Rieger Armin
FA722C0904	Unraveling the mechanisms of octenidine dihydrochloride efficacy on human skin.	Dermatologie_722	Elbe-Bürger Adelheid
FA722C1601	"Deciphering genomic aberrations in rare skin cancers to find mechanism-based treatment strategies"	Dermatologie_722	Wiesner Thomas
FW722A0101	Resistance to scabicides	Dermatologie_722	Handisurya Alessandra
FW722A0201	CSI granuloma-cell-type specific interactions in granulomas.	Dermatologie_722	Kopf Aglaja
FW722A0301	Co-receptors of CD8+ T cells in chronic skin inflammation	Dermatologie_722	Sary Georg
FA751B0109	A multicenter, prospective, observational study to evaluate the use of the sFlt-1/PlGF ratio in the risk stratification of pregnant women with signs and symptoms of preeclampsia or diagnosed preeclampsia in current clinical practice	Frauenheilkunde_751	Zeisler Harald
FA751B0702	Aurikuläre Vagus-Nerv-Stimulation in der Geburtshilfe - eine prospektive, randomisierte Doppelblindstudie	Frauenheilkunde_751	Farr Alex
FA751C0136	MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-centre phase III Trial including LOGOS	Frauenheilkunde_751	Polterauer Stephan

FA751C0211	Tumor Suppressor Protein Aggregation Determines Response to Olaparib	Frauenheilkunde_751	Zeillinger Robert
FA751C0518	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women	Frauenheilkunde_751	Wenzl René
FA751C0632	A randomised, double-blind, parallel group, placebo-controlled multi-centre phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in BRCA mutated high risk HER2-negative breast cancer patients who have completed definitive treatment and neoadjuvant or adjuvant chemotherapy	Frauenheilkunde_751	Singer Christian
FA751C0667	Austrian BRCA-associated metastatic breast cancer registry	Frauenheilkunde_751	Singer Christian
FA751C0681	A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2- Negative Breast Cancer	Frauenheilkunde_751	Singer Christian
FA751C0683	Tucatinib bei Patienten mit lokal fortgeschrittenem oder metastasiertem HER2+ Mammakarzinom, die zuvor mit mindestens zwei anti-HER2-basierten Therapieregimen behandelt wurden: eine multizentrische, internationale, prospektive, nicht-interventionelle Studie in Deutschland und Österreich	Frauenheilkunde_751	Singer Christian
FA751C0902	Internationale, prospektive, multizentrische Beobachtungsstudie zum "Patient Reported Outcome" bei primärer oder sekundärer Brustrekonstruktion nach Mastektomie mit einem titanisierten Polypropylen-Netz (TiLOOP® Bra Pocket)	Frauenheilkunde_751	Gschwantler-Kaulich Daphne

FA751C1208	Video-assisted genetic counselling for hereditary Cancer	Frauenheilkunde_751	Pfeiler Georg
FA751C1210	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks in women with, or at high risk for developing hormone-receptor positive breast cancer	Frauenheilkunde_751	Pfeiler Georg
FA751C1607	A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy	Frauenheilkunde_751	Concin Nicole
FA751C1801	Die Effekte von Präbiotika bei Patientinnen mit Ovarialkarzinom unter Chemotherapie - Pilotstudie	Frauenheilkunde_751	Aust Stefanie
FA751C1901	Treatment regimens and outcomes of BC patients with BRCA gene variants – a study of the ATHENA registry	Frauenheilkunde_751	Tan Yen Yen
FA751C2101	A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)” and any amendments thereto	Frauenheilkunde_751	Seifert Michael
FA751C2102	A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant	Frauenheilkunde_751	Seifert Michael

	Endocrine-Based Therapy Without Disease Recurrence		
FA751C2401	Evaluating ovarian reserve after conventional laparoscopy versus robotic surgery for bilateral endometrioma: a prospective, randomized controlled trial	Frauenheilkunde_751	Bekos Christine
FA751D1401	Messung der Körperkerntemperatur zur Bestimmung der fertilen Tage bei Frauen mit polyzystischem Ovarsyndrom – eine prospektive Kohorten-Pilotstudie	Frauenheilkunde_751	Hager Marlene
FA751C0682	A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer	Frauenheilkunde_751	Singer Christian
FA744A0202	Effects of locally applied glucocorticoids and selective glucocorticoid receptor agonists on the inner ear in an animal model	Hals-, Nasen- und Ohrenkrankheiten_74 4	Arnoldner Christoph
FA744B0905	Identification of biomarkers for diagnosis of various forms of chronic rhinosinusitis (including N-ERD) in serum and nasal secretions using proximity extension assay technology	Hals-, Nasen- und Ohrenkrankheiten_74 4	Schneider Sven-Thorben
FA744B1103	A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).” Debio 1143-SCCHN-301	Hals-, Nasen- und Ohrenkrankheiten_74 4	Heiduschka Gregor
FA744B1105	A phase 1 study of FluBHPVE6E7 immunotherapy in patients with	Hals-, Nasen- und Ohrenkrankheiten_74 4	Heiduschka Gregor

	HPV16-associated oropharyngeal squamous cell carcinoma		
FA744B1202	Moving towards PREcision Medicine In United airways disease: Unravel-ling inflamMatory patterns in asthmatic patients with or without nasal polyps (PREMIUM) – an exploratory pilot study	Hals-, Nasen- und Ohrenkrankheiten_744	Eckl-Dorna Julia
FA744B1403	Evaluierung der Roboter-gestützten Cochlea Implantation (HEARO) an Leichenpräparaten - Nachfolgeprojekt	Hals-, Nasen- und Ohrenkrankheiten_744	Gstöttner Wolfgang
FA731C1410	Educational Grant - Heart Failure Personal - Anstellungskosten	Herzchirurgie_732	Zimpfer Daniel
FA731C2102	Intuity Database	Herzchirurgie_732	Andreas Martin
FA731C2203	Forschungsprojekt Xenios: "Efficassy i-cor-synchronised cardiac assist"	Herzchirurgie_732	Zimpfer Daniel
FA732A0306	ASCEND - eine klinische Nachuntersuchung nach dem Inverkehrbringen bei Patienten, die mit der ON-X Aortenprothese (AAP) behandelt wurden	Herzchirurgie_732	Andreas Martin
FA732A0307	TRICUS REGISTRY - Retrospektive, prospektive, multizentrische klinische Nachuntersuchung von Patienten mit schwerer Tricuspidalinsuffizienz nach Behandlung mit dem Tric-Valve Transkatheter-Bikavalven-System	Herzchirurgie_732	Andreas Martin
FA732A0404	Ausbildungsvertrag - VAD Coordinator Course / HeartMate 3TM LVAS Training	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0406	Herstellung von Berlin Heart Mini-VAD Driveline Samples mittels Extrusion und Bestimmung der mechanischen Eigenschaften	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0407	Human/Machine Interface: What the HeartMate 3 [®] Device Tells Us About the Future	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0501	Feasibility study of a novel cavopulmonary assist device	Herzchirurgie_732	Granegger Marcus
FA732A0505	Development of a novel cavopulmonary assist device	Herzchirurgie_732	Granegger Marcus
FA732A0506	Development of a novel cavopulmonary assist device	Herzchirurgie_732	Granegger Marcus

FA732A0507	Kreislaufjustierung bei Non-Surgical Stage 1 Verfahren bei Hypoplastischem Linksherzsyndrom	Herzchirurgie_732	Granegger Marcus
FA732A0801	The One Month Dual Antiplatelet Therapy With Ticagrelor in CABG Patients (ODIN) trial	Herzchirurgie_732	Sandner Sigrid
UE73206001	Transcatheter Aortic Valve Fellowship THV-F23-041	Herzchirurgie_732	Andreas Martin
UE73206002	Forschungsförderung GIGAX Stiftung	Herzchirurgie_732	Zimpfer Daniel
FA629A0302	NEUcrest	Hirnforschung_360	Adameyko Igor
FA684A0103	Identification of readouts for the evaluation of treatment strategies in RCDP	Hirnforschung_360	Berger Johannes
FA684A0105	Cooperation Med-Life Discovery (MLD) ether lipid deficiency	Hirnforschung_360	Berger Johannes
FA711A0313	A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)“	Innere Medizin I_711	Burgmann Heinz
FA711A0316	PHASE II MULTICENTER STUDY OF EXTRACORPOREAL PHOTOPHERESIS WITH UVADEX™ PLUS STANDARD STEROID TREATMENT FOR HIGH RISK ACUTE GRAFT-VERSUS-HOST DISEASE	Innere Medizin I_711	Burgmann Heinz
FA711A0602	FFG Talente-Praktikum 2023 Infektionsbiologie	Innere Medizin I_711	Starkl Philipp
FA711A0603	VALANX Hypersensitivity	Innere Medizin I_711	Starkl Philipp
FA711B0572	A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy	Innere Medizin I_711	Preusser Matthias
FA711B0719	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomized phase III study	Innere Medizin I_711	Preusser Matthias

FA711B0925	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma	Innere Medizin I_711	Preusser Matthias
FA711B0933	A phase 1/2, open-label study, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 510 Monotherapy in subjects with advanced solid tumors with KRAS p.G12C mutation and AMG 510 Combination Therapy in subjects with advanced NSCLC with KRAS p.G12C mutation	Innere Medizin I_711	Preusser Matthias
FA711B0967	a phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety and pharmacokinetics of Atezolizumab given in combination with Cabozantinib versus Docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy	Innere Medizin I_711	Preusser Matthias
FA711B0992	Offene, randomisierte, kontrollierte globale Studie der Phase III mit Telisotuzumab-Vedotin (ABBV 399) im Vergleich zu Docetaxel bei Patienten mit vorbehandeltem, c-Met-überexprimiertem und lokal fortgeschrittenem/metastasierendem Nicht-Plattenepithel-, nicht kleinzelligem Lungenkarzinom (NSCLC) mit EGFR-Wildtyp	Innere Medizin I_711	Preusser Matthias
FA711B1015	An open-label, multi-center, dose-escalation Phase Ib study to determine the recommended phase 2 dose of APN 401 in patients with advanced solid tumors	Innere Medizin I_711	Preusser Matthias

FA711B1016	A Multicenter, Single-Arm, Three Cohort, Phase II Trial of Patritumab Deruxtecan (HER3-DXD) in Patients with Active Brain Metastases from Metastatic Breast Cancer and Non-Small Cell Lung Cancer, and in Patients with Lepomeningeal Carcinomatosis from Advanced Solid Tumors (The TUXEDO-3 Study)	Innere Medizin I_711	Preusser Matthias
FA711B1017	Personalized targeted glioblastoma therapies by ex vivo drug screening: Advanced brain Tumor TheRApy Clinical Trial	Innere Medizin I_711	Preusser Matthias
FA711B1018	Main study: Multicentre, multi-country, prospective, observational, post authorisation safety study to describe the incidence of discontinuation due to diarrhoea within the first 3 months of treatment with Neratinib, in adult breast cancer patients treated in extended adjuvant in a real world setting: the NERLYFE study. Ancillary study: A Nerlyfe ancillary study to describe recurrence in breast cancer patients treated with Neratinib in a real-world setting.	Innere Medizin I_711	Preusser Matthias
FA711B1019	Nachweise aus der klinischen Praxis zum langfristigen Überleben von Patienten mit metastasiertem duktalem Adenokarzinom des Pankreas (mPDAC) nach der Behandlung mit liposomalem Irinotecan	Innere Medizin I_711	Preusser Matthias
FA711B1020	Eine randomisierte, offene, multizentrische, globale Phase-III-Prüfung zu Datopotamab-Deruxtecan (Dato-DXd) in Kombination mit Durvalumab und Carboplatin im Vergleich zu Pembrolizumab in Kombination mit einer platinbasierten Chemotherapie zur Erstlinienbehandlung von Patienten mit lokal	Innere Medizin I_711	Preusser Matthias

	fortgeschrittenem oder metastasiertem NSCLC ohne verwertbare genomische Veränderungen		
FA711B1021	Eine randomisierte, multizentrische, offene Studie der Phase III zu Lurbinectedin als Monotherapie oder Lurbinectedin in Kombination mit Irinotecan verglichen mit der Präferenz des Prüfarztes (Topotecan oder Irinotecan) bei Patienten mit rezidivierendem kleinzelligem Lungenkrebs (SCLC)	Innere Medizin I_711	Preusser Matthias
FA711B1022	A multicenter, single-arm, three cohort, Phase II Trial of Patritumab Deruxtecan (HER3-DXD) in patients with active brain metastases from metastatic breast cancer and non-small cell lung cancer, and in patients with leptomeningeal carcinomatosis from advanced solid tumors (The TUXEDO-3 Study)	Innere Medizin I_711	Preusser Matthias
FA711B1023	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study	Innere Medizin I_711	Preusser Matthias
FA711B1024	A Randomised Phase III Open Label Study of regorafenib+nivolumab cs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Innere Medizin I_711	Preusser Matthias
FA711C0913	An open-label, single-arm multicentre Phase 1b study to evaluate the safety, efficacy and pharmacokinetics of multiple doses of ELA026 in adults and adolescents with sHLH	Innere Medizin I_711	Valent Peter

FA711C0925	Thromboembolic risk and mortality of patients with Cold Agglutinin Disease (CAD) in European countries: A Retrospective Chart review	Innere Medizin I_711	Valent Peter
FA711C0936	A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide	Innere Medizin I_711	Valent Peter
FA711C0937	A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy	Innere Medizin I_711	Valent Peter
FA711C0938	Zanubrutinib (Brukinsa®) bei Patienten mit Morbus Waldenström (MW), Chronisch Lymphatischer Leukämie (CLL) und Marginalzonen Lymphom (MZL) - eine prospektive, multizentrische, nicht-interventionelle Studie (ARIADNE)	Innere Medizin I_711	Valent Peter
FA711C0939	NIS GO Pfizer	Innere Medizin I_711	Valent Peter
FA711C0940	Eine multizentrische, randomisierte, doppelblinde Phase-IIb-Studie zur Sicherheit und Wirksamkeit von TAK-755 (rADAMTS13) mit minimalem oder ohne Plasmaaustausch (PEX) bei der Behandlung von immunvermittelter thrombotisch-	Innere Medizin I_711	Valent Peter

	thrombozytopenischer Purpura (iTTP)		
FA711C0941	A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25)	Innere Medizin I_711	Valent Peter
FA711C0942	An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)	Innere Medizin I_711	Valent Peter
FA711C0943	A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma	Innere Medizin I_711	Valent Peter
FA711C0944	A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel (Ide-Cel) with Lenalidomide (LEN) Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response After Autologous Stem Cell Transplantation (ASCT)	Innere Medizin I_711	Valent Peter
FA711C0945	Eine randomisierte, kontrollierte Phase-III-Studie zu Blinatumomab im Wechsel mit einer Chemotherapie mit geringer Intensität versus der Standardbehandlung bei älteren Erwachsenen mit neu diagnostizierter	Innere Medizin I_711	Valent Peter

	Philadelphia-negativer B-Zell-Vorläufer-ALL (akuter lymphatischer Leukämie) mit einer Sicherheits-Run-In-Phase (Golden-Gate-Studie)		
FA711C0946	AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANTINELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA (MAGNETISMM-6)	Innere Medizin I_711	Valent Peter
FA711C0947	IM048-022 and A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Ibrandomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)	Innere Medizin I_711	Valent Peter
FA711C0948	A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments	Innere Medizin I_711	Valent Peter
FA711C1049	A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Innere Medizin I_711	Jäger Ulrich
FA711C1050	Comprehensive genomic profiling and next generation functional drug screening for patients with aggressive haematological malignancies: next generation personal medicine	Innere Medizin I_711	Valent Peter

FA711C1057	Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL	Innere Medizin I_711	Jäger Ulrich
FA711C1058	A prospective, multicenter, non-interventional, observational, post-authorisation safety study of Ropeginterferon alfa-2b in polycythemia vera patients (BESREMi-PASS)	Innere Medizin I_711	Valent Peter
FA711C1058	A prospective, multicenter, non-interventional, observational, post-authorisation safety study of Ropeginterferon alfa-2b in polycythemia vera patients (BESREMi-PASS)	Innere Medizin I_711	Valent Peter
FA711C1079	ESMART: Supporting Myeloma Patients using the Advanced Symptom Management System (ASYMS) Remote Technology	Innere Medizin I_711	Valent Peter
FA711C1083	Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	Innere Medizin I_711	Jäger Ulrich
FA711C1084	Supporting CLL Patients using the Advanced Symptom Management System (ASYMS) Remote Technolog	Innere Medizin I_711	Valent Peter
FA711C1097	eSMART: Verlaufsuntersuchung von Lebensqualität bei Krebspatienten der Abteilung für Hämatologie mittels der psychoonkologischen Basisdiagnostik	Innere Medizin I_711	Valent Peter
FA711C1318	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (INCB050465)	Innere Medizin I_711	Jäger Ulrich
FA711C1320	A Phase 2, Open-label, Multicenter, Rollover Study to Provide Continued Treatment for	Innere Medizin I_711	Jäger Ulrich

	Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)		
FA711C1414	A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥ 12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIII-Fc-VWF-XTEN; efanesoctocog alfa) for 24 months	Innere Medizin I_711	Ay Cihan
FA711C1415	Open-label safety study in adults and adolescents with haemophilia A with and without FVIII inhibitors switching directly from emicizumab prophylaxis to NNC0365-3769 (Mim8) prophylaxis; Protocol ID: NN7769-4728	Innere Medizin I_711	Ay Cihan
FA711C1416	Takeda Educational Grant 2023 für Tätigkeiten junger Kolleg*innen und Personal im medizinischen Bereich der Hämostaseologie	Innere Medizin I_711	Ay Cihan
FA711C1417	Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors; Protocol ID: NN7769-4532 (Frontier 4)	Innere Medizin I_711	Ay Cihan
FA711C1418	Sobi Medical Grant 2023: Real world data on the use of TPO-RAs in patients after hematopoietic stem cell transplantation	Innere Medizin I_711	Ay Cihan
FA711C1419	Effect of incorporating individual pharmacokinetic results in routine clinical care on bleeding and factor consumption in severe hemophilia A	Innere Medizin I_711	Ay Cihan
FA711C1420	Retrospektive Analyse von Daten zur Lebensqualität von ITP-Patient:innen im Rahmen der Vienna ITP Biobank (Novartis)	Innere Medizin I_711	Ay Cihan

FA711D0304	Improving maternal and infant health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women–MAMAH	Innere Medizin I_711	Burgmann Heinz
FA711D0312	EU Three Rapid Diagnostic tests (Point-of-Care) for COVID-19 Coronavirus, improving epidemic preparedness, and foster public health and socio-economic benefits	Innere Medizin I_711	Burgmann Heinz
FA711D0315	Observational Study on the Clinical Use of EVUSHELD (AZD7442) in Austria	Innere Medizin I_711	Burgmann Heinz
UE71106010	Personalkostenförderung Studieninfrastruktur	Innere Medizin I_711	Valent Peter
FA714B0394	Eine offene Verlängerungsstudie zur Bewertung der Sicherheit, Verträglichkeit und Wirksamkeit der Langzeitanwendung von Treprostinil-Palmitil-Inhalationspulver bei Patienten mit pulmonaler arterieller Hypertonie	Innere Medizin II_714	Lang Irene
FA714B0395	Register zum Behandlungsansatz in der multimodalen Ära (TEAM)	Innere Medizin II_714	Lang Irene
FA714B0396	Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in PAH group I patients.	Innere Medizin II_714	Lang Irene
FA714B0541	Porcine acute myocardial infarction model for immune cell profiling and therapy”	Innere Medizin II_714	Pavone-Gyöngyösi Mariann
FA714B2016	iCARE4CVD (EU-Projekt)	Innere Medizin II_714	Hülsmann Martin
FA714B3105	Doppelblinde, randomisierte, placebokontrollierte, multizentrische Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Vutrisiran bei Patienten mit Transthyretin-Amyloidose mit Kardiomyopathie	Innere Medizin II_714	Kastner Johannes

	(ATTR - Amyloidose mit Kardiomyopathie)		
FA714B3113	An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM). / Eine Open-Label-Verlängerungsstudie zur Beurteilung der langfristigen Sicherheit von Eplontersen (ION-682884) bei Patienten mit Transthyretin-vermittelter Amyloid-Kardiomyopathie (ATTR-CM)	Innere Medizin II_714	Kastner Johannes
FA714B4204	RHEIA - A Prospective, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Transcatheter Aortic Valve Implantation in Female Patients who have Severe Symptomatic Aortic Stenosis Requiring Aortic Valve Replacement	Innere Medizin II_714	Hengstenberg Christian
FA714B4208	Spiroergometrie Register zur Evaluierung von prognostischen Faktoren bei Herzerkrankungen – ein monozentrisches, retrospektives und prospektives Register	Innere Medizin II_714	Badr Eslam Roza
FA714B4304	A Multicenter, Cross-sectional study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients with Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)	Innere Medizin II_714	Speidl Walter
FA714B4503	Catheter-Based Ablation of atrial fibrillation compared to conventional treatment in patients with Heart Failure with Preserved Ejection Fraction -	Innere Medizin II_714	Schönbauer Robert

	CABA-HFPEF (CABA-HFPEF-DZHK27)		
FA714B4912	AGMB-129-C102	Innere Medizin II_714	Kastl Stefan
FA714B5002	FARADISE: Real world Data collection in subjects treated with the FARAPULSE™ Pulsed Field Ablation system”	Innere Medizin II_714	Stojkovic Stefan
FA714B5401	COVID-19 Infektion und chronisch thromboembolische Lungenerkrankung (chronisch throm-boembolische pulmonale Hypertension, CTEPH und chronisch thromboembolische Erkrankung, CTEPD) - Pilotstudie	Innere Medizin II_714	Skoro-Sajer Nika
FA714B5502	Educational Grant - AMICUS	Innere Medizin II_714	Gatterer Constantin
FA714B5801	"Novel biomarkers"	Innere Medizin II_714	Mayr Manuel
FA714C1101	Blood donation to investigate ex vivo blood activation in a hemodialysis circuit	Innere Medizin II_714	Brunner-Ziegler Sophie
FA714D0504	Wirksamkeit und Sicherheit von Benralizumab im Real-World Setting in Patienten mit schwerem eosinophilem Asthma in Wien - (BEHAVE) 1.1. Projekttitle (Englisch): The real-world effectiveness and safety of Benralizumab in patients with severe eosinophilic asthma in Vienna – (BEHAVE)	Innere Medizin II_714	Idzko Marco
FA714D0508	Eine randomisierte, placebokontrollierte Multikohortenstudie der Phase IIa zur Bewertung der Sicherheit, Pharmakokinetik, Pharmakodynamik und klinischen Aktivität von ansteigenden Dosen von RXC007 bei Patienten mit idiopathischer Lungenfibrose.	Innere Medizin II_714	Idzko Marco
FA714D0802	IMPALLA - IMPAct of ArtiQ.PFT, an artificial intelLigence bAsed data interpretation tool, on improving the diagnosis and referral process for ILD patients.	Innere Medizin II_714	Gompelmann Daniela

UE71406016	Durchführung einer retrospektiven multizentrischen Erhebung zur Indikation und Wirksamkeit von Cangrelor bei perkutanter Koronarintervention	Innere Medizin II_714	Siller-Matula Jolanta
UE71406018	Forschungszuwendungen	Innere Medizin II_714	Hemetsberger Rayyan
UE71406019	Epidemiologie des Patientenkollektivs in einer kardiologischen Ambulanz - Kardio-Onkologie	Innere Medizin II_714	Bergler-Klein Jutta
FA714B4703	doppelblinde, randomisierte, Placebo-kontrollierte, multizentrische, internationale Parallelgruppenstudie der Phase III zur Beurteilung der Sicherheit, Verträglichkeit und Wirksamkeit von Mavacamten im Vergleich zu Placebo bei Teilnehmern mit symptomatischer nHCM (nichtobstruktiver, hypertrophischer Kardiomyopathie (non-obstructive Hypertrophic Cardiomyopathy))	Innere Medizin II_714	Badr Eslam Roza
FA716B0309	GOS 52621-06	Innere Medizin III_716	Scherer Thomas
FA716B0612	Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant` to be conducted according to the Protocol.	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B0615	The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B0618	Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT)	Innere Medizin III_716	Kautzky-Willer Alexandra

FA716B0623	A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4).	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B0624	Federated virtual twins for privacy-preserving personalised outcome prediction of type 2 diabetes treatment.	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B1002	Eine randomisierte, doppelblinde, Placebo kontrollierte Studie zur Bewertung der Sicherheit und Wirksamkeit von Crinecerfont (NBI-74788) bei erwachsenen Patienten mit klassischem kongenitalem adrenogenitalem Syndrom, gefolgt von einer unverblindeten Behandlung	Innere Medizin III_716	Kiefer Florian
FA716B1403	PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism-Erweiterung des Wissenstandes von Ärzten bezüglich Hypoparathyreoidismus): Eine Registrierstudie für Studienteilnehmer mit chronischem Hypoparathyreoidismus	Innere Medizin III_716	Vila Greisa
FA716B1405	Thiazide treatment in permanent hypoparathyroidism	Innere Medizin III_716	Vila Greisa
FA716B1901	Tracking Nutrient Metabolism and Cellular Partitioning by Multimodal Molecular Imaging - WWTF Life Sciences Call 2019	Innere Medizin III_716	Krssak Martin
FA716C1020	Genomics-based immunological risk stratification in kidney transplantation	Innere Medizin III_716	Oberbauer Rainer
FA716D0610	Eine randomisierte, aktiv-kontrollierte Phase-3b/4-Parallelgruppenstudie zu Baricitinib bei Patienten mit rheumatoider Arthritis	Innere Medizin III_716	Scheinecker Clemens

FA716D0612	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS	Innere Medizin III_716	Scheinecker Clemens
FA716D0717	Primary Immunodeficiencies - Austrian Register	Innere Medizin III_716	Scheinecker Clemens
FA716D0717	Primary Immunodeficiencies - Austrian Register	Innere Medizin III_716	Scheinecker Clemens
FA716D0721	A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis	Innere Medizin III_716	Scheinecker Clemens
FA716D0810	Eine Populations-basierte prospektive klinische Studie zur Effektivität und Sicherheit der Covid-19 Auffrischungsimpfung	Innere Medizin III_716	Aletaha Daniel
FA716D1302	Targeting the type I interferon (IFN) receptor in rheumatoid arthritis (RA) patients with a high IFN signature – A multicenter, randomised, double-blind, placebo-controlled Phase 2A/ proof-of-concept study to evaluate the efficacy and safety of an intravenous treatment regimen of 300 mg Anifrolumab versus placebo in patients with moderately to severely active RA who did not respond to biological disease-modifying anti-rheumatic drugs (bDMARDs) and who have a high IFN-signature	Innere Medizin III_716	Smolen Josef
FA716D1403	Schwangerschaftsregister für Patientinnen mit rheumatischen Erkrankungen & Familienplanung/-Gründung	Innere Medizin III_716	Mazzucato- Puchner Antonia
FA716D1403	Schwangerschaftsregister für Patientinnen mit rheumatischen Erkrankungen & Familienplanung/-Gründung	Innere Medizin III_716	Mazzucato- Puchner Antonia

FA716D1501	in vitro effect of the JAK-1 inhibitor upadacitinib on murine osteoclastogenesis	Innere Medizin III_716	Hayer Silvia
FA716D1702	EU Stratification of Rheumatoid Arthritis: Computational models to personalise management strategies for difficult-to-Treat disease	Innere Medizin III_716	Studenic Paul
FA716D2001	Funding IMI project RTCure	Innere Medizin III_716	Bonelli Michael
FA716D2002	Cell profiling of pan versus selective JAKinibs in healthy controls and RA patients	Innere Medizin III_716	Bonelli Michael
FA716D2101	BGP in osteoarthritis	Innere Medizin III_716	Mandl Peter
FA716D2101	BGP in osteoarthritis	Innere Medizin III_716	Mandl Peter
FA716D2301	A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis	Innere Medizin III_716	Bobacz Klaus
FA716E0855	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Innere Medizin III_716	Trauner Michael
FA716E0858	A randomized, multi-center phase III study of Nivolumab versus Sorafenib as first-line treatment in patients with advanced HCC	Innere Medizin III_716	Trauner Michael
FA716E0867	A Phase 3 multicenter, open-label extension (OLE) Study to evaluate the long-term safety and efficacy of ABT-494 in subjects with ulcerative colitis (UC)	Innere Medizin III_716	Trauner Michael
FA716E0876	A Phase 2, double-blind, randomized Study evaluating the safety, tolerability, and efficacy of GS-4997 in combination with Prednisolone versus Prednisolone	Innere Medizin III_716	Trauner Michael

	alone in subjects with severe alcoholic Hepatitis (AH)		
FA716E0877	A Long-Term Extension Study to evaluate the safety of filgotinib in subjects with ulcerative colitis	Innere Medizin III_716	Trauner Michael
FA716E0878	A Long Term Extension study to evaluate the safety of filgotinib subjects with crohns disease	Innere Medizin III_716	Trauner Michael
FA716E0903	A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks versus Standard of Care in Wilson Disease Patients Aged 18 and Older with an Extension Phase of up to 60 Months	Innere Medizin III_716	Trauner Michael
FA716E0943	Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality	Innere Medizin III_716	Trauner Michael
FA716E0956	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis	Innere Medizin III_716	Trauner Michael
FA716E0961	"A Pilot Open Label, Multi-dose, Phase 2 Study to Assess Changes in a Novel Histological Activity Scale in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)	Innere Medizin III_716	Trauner Michael
FA716E0967	Randomized, placebo-controlled, double blind, multi-centre Phase IIb stuDy to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER	Innere Medizin III_716	Trauner Michael

FA716E0968	WO41535 - A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION	Innere Medizin III_716	Trauner Michael
FA716E0978	ACUSON Sequoia Ultrasound System	Innere Medizin III_716	Trauner Michael
FA716E0984	Elimination of Hepatitis C in Eastern Austria	Innere Medizin III_716	Trauner Michael
FA716E0989	Diagnoseerstellung und Risikostratifizierung von Lebererkrankungen mittels Deep Learning anhand von klinischen Routinedaten	Innere Medizin III_716	Trauner Michael
FA716E0991	A multicenter observational, phase 4 study to evaluate the safety and tolerability of lenvatinib in patients with advanced or unresectable hepatocellular carcinoma	Innere Medizin III_716	Trauner Michael
FA716E0994	A multinational observational registry collecting data on the profile of patients with chronic hepatitis D virus infection receiving treatment with bulevirtide	Innere Medizin III_716	Trauner Michael
FA716E1001	A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease	Innere Medizin III_716	Trauner Michael
FA716E1007	Role of Bile Acid Signaling in Liver Sinusoidal endothelial cell-mediated liver regeneration	Innere Medizin III_716	Trauner Michael
FA716E1012	A phase IIb, double-blind, randomised, placebo-controlled, trial to evaluate the efficacy and tolerability of ZED1227 in celiac	Innere Medizin III_716	Trauner Michael

	disease subjects experiencing symptoms despite gluten-free diet		
FA716E1021	Prediction of endoscopic features of disease from single-cell RNA sequencing data in sigmoid colon of patients with ulcerative colitis	Innere Medizin III_716	Trauner Michael
FA716E1036	Pharmacokinetic (PK) study to investigate the pharmacokinetic profile of norucholic acid (NCA) in primary sclerosing cholangitis (PSC) patients treated with NCA capsules within open-label extension (OLE) NUC-5/PSC	Innere Medizin III_716	Trauner Michael
FA716E1037	Rolle von Norurcholsäure (NCA) bei der Therapie von cholestatischen und metabolischen Lebererkrankungen und Malignomen der Leber	Innere Medizin III_716	Trauner Michael
FA716E1038	Disease-driving mechanisms in patients with portal hypertension	Innere Medizin III_716	Trauner Michael
FA716E1039	A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS 5290 in Participants With Moderately to Severely Active Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E1040	AGMB-129-C102	Innere Medizin III_716	Trauner Michael
FA716E1041	NUC-005/PSC Prüfleiter	Innere Medizin III_716	Trauner Michael
FA716E1042	Practice Change at Scale – Nationales HCC-Register	Innere Medizin III_716	Trauner Michael
FA716E1043	A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease	Innere Medizin III_716	Trauner Michael
FA716E1044	A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis	Innere Medizin III_716	Trauner Michael

FA716E1045	EVALUATE THE FUNCTION OF TMEM16A POTENTIATOR IN NAÏVE AND MDR2 KO MICE	Innere Medizin III_716	Trauner Michael
FA716E1046	Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of one dose (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in decompensated cirrhosis after their first decompensation event, who are stabilized CTP 5-7	Innere Medizin III_716	Trauner Michael
FA716E1047	Pan Tumor Study for longterm follow up of cancer survivors who have participated in trials investigating nivolumab	Innere Medizin III_716	Trauner Michael
FA716E1048	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)	Innere Medizin III_716	Trauner Michael
FW716D0101	Dendritic cells as precursors of osteoclasts	Innere Medizin III_716	Blüml Stephan
FA716D2201	The clinical utility of IRF5 activation status in RMDs	Innere Medizin III_716	Heinz Leonhard
FA781B1604	Set-up and maintenance of a national Neurofibromatosis database in Austria	Kinder- und Jugendheilkunde_781	Azizi Amedeo
FA781B1907	ERN EpiCARE	Kinder- und Jugendheilkunde_781	Feucht Martha
FA781B2205	Junior Research Academy	Kinder- und Jugendheilkunde_781	Weiler-Wichtl Liesa
FA781B2601	A randomized multicenter open-label controlled trial to show that mucous fistula refeeding reduces the time from enterostomy closure to full enteral feeds (MUCous Fistula REfeeding (Kurztitel "MUC-FIRE" trial)	Kinder- und Jugendheilkunde_781	Binder Christoph
FA781B3205	Secured Access to innovative medicines for CHildren, adolescents and young adults with cAncer	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon

FA781B3206	ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3401	"Gene Fusions" - New Detectable Targets in Liquid Biopsy Samples of Pediatric Brain Tumors (Oncomine Clinical Grant Program)	Kinder- und Jugendheilkunde_781	Madlener Sibylle
FA781B3505	EPILEPSY-RARE Vienna - Seltene Epilepsien bei Kindern und Jugendlichen – Prospektives Register zur Beschreibung des Verlaufs, der Anfallslast und des Outcomes kindlicher Epilepsiesyndrome an der Medizinischen Universität Wien	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
FA781B3601	ReConNect: RemoteConsulting4NeonatalResuscitation - eine simulationsbasierte Pilotstudie	Kinder- und Jugendheilkunde_781	Rittenschober-Böhm Judith
FA781D0444	Multizentrische, offene Studie zur Untersuchung der Wirksamkeit und Sicherheit von AOP Landiolol zur Regulierung supraventrikulärer Tachykardien bei pädiatrischen Patienten (LANDI-PED)	Kinder- und Jugendheilkunde_781	Michel-Behnke Ina
FA781D0614	A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients \geq 12 years of age with severe hemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebraqd Factor-XTEN fusion protein (rFVIII Fc-VWF-XTEN; efanesoctocog alfa) for 24 months	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0615	Safety of dabigatran etexilate (DE) for treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from birth to	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph

	less than 2 years of age: a prospective European non-interventional cohort study based on new data collection		
FA781D0616	Evidence-based Feasibility (EbF) for BioMarin's protocol in severe Hemophilia A adolescentsw	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0701	Evaluation of bone mineral density and bone turnover parameters in children with severe hemophilia A and B receiving factor or non-factor treatment	Kinder- und Jugendheilkunde_781	Thom Katharina
FA781F0209	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parellel-group, Outpatient Stuy Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate to Severe Atopic Dermatitis	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F0211	Wirksamkeit und Sicherheit der sublingualen SQ-tree-Immuntherapie-Tablette bei Kindern und Jugendlichen (im Alter zwischen 5 und 17 Jahren) mit mäßiger bis schwerer durch Birkenpollen und Pollen der Birken-homologen Gruppe ausgelöster allergischer Rhinitis und/oder Konjunktivitis	Kinder- und Jugendheilkunde_781	Szépfalusi Zsolt
FA781F0607	Optimization of management and quality of life of patients with lysosomal storage disorders	Kinder- und Jugendheilkunde_781	Konstantopoulou Vassiliki
FA781F0906	INNODIA iVZW	Kinder- und Jugendheilkunde_781	Rami-Merhar Birgit
FA781F1005	Testung auf Saure-Lysosomale-Lipase-Defizienz (LAL-D)	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1014	Forensische Kinder- und Jugenduntersuchungsstelle FOKUS	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
FA781F1102	Modellierung der Mechanismen von Corpus Callosum assoziierten Erkrankung in zerebralen Organoiden	Kinder- und Jugendheilkunde_781	Seidl Rainer

FA781F1203	A Randomized, Double blind, Placebo controlled, Ascending Multiple dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis Imperfecta	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F1204	Rare disease, more rare diagnosis: Mapping the accuracy of laboratory screening for rare bone disorders in Austria	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F1904	RARE: psychoedukatives unterstützungsprogramm für Kinder mit seltenen Krankheiten	Kinder- und Jugendheilkunde_781	Vodopiutz Julia
FA781F2101	Innovative digitale Messmethoden zur Feststellung der Fahrtüchtigkeit	Kinder- und Jugendheilkunde_781	Felnhofer Anna
FA781G0113	Secondary Analysis of data of the phase II trial to evaluate efficacy of PD-protec® in peritoneal dialysis in patients with chronic renal failure – MAPE3	Kinder- und Jugendheilkunde_781	Aufricht Christoph
FA781G0113	Secondary Analysis of data of the phase II trial to evaluate efficacy of PD-protec® in peritoneal dialysis in patients with chronic renal failure – MAPE3	Kinder- und Jugendheilkunde_781	Aufricht Christoph
FA781G0205	MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)	Kinder- und Jugendheilkunde_781	Huber Wolf-Dietrich
FA781G0206	MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC	Kinder- und Jugendheilkunde_781	Huber Wolf-Dietrich
FA781G0404	An Observational Registry Study To Evaluate The Use And Safety Of Cinacalcet Among Paediatric Patients With Secondary Hyperparathyroidism	Kinder- und Jugendheilkunde_781	Arbeiter Klaus

FA781G0902	SaroMyrD4FSGS	Kinder- und Jugendheilkunde_781	Daniel-Fischer Lisa
UE78106012	Neuropsychologische und sozioemotionale Aspekte von Neurofibromatose differenzierter erforschen	Kinder- und Jugendheilkunde_781	Pletschko Thomas
UE78106014	EOPD - Mobiler Psychologischer Dienst	Kinder- und Jugendheilkunde_781	Leiss Ulrike
UE78106019	Personalkosten Onko-Team	Kinder- und Jugendheilkunde_781	Peyrl Andreas
UE78106020	Personalkosten Prolacta	Kinder- und Jugendheilkunde_781	Binder Christoph
UE78106021	Neurofeedback bei Neurofibromatose	Kinder- und Jugendheilkunde_781	Pletschko Thomas
UE78106023	Loss of T cell tolerance in actin-related immunodeficiencies	Kinder- und Jugendheilkunde_781	Salzer Elisabeth
FA781F2001	Reconstruction and Computational Modelling for Inherited Metabolic Diseases	Kinder- und Jugendheilkunde_781	Möslinger Dorothea
FA765A0803	Home Treatment	Kinder- und Jugendpsychiatrie_765	Plener Paul
FA765A0804	Home Treatment - Begleitforschung	Kinder- und Jugendpsychiatrie_765	Plener Paul
FA765A0804	Home Treatment - Begleitforschung	Kinder- und Jugendpsychiatrie_765	Plener Paul
UE76506002	Digitale Gesundheitsanwendung in der Kinder- und Jugendpsychiatrie-Phase I	Kinder- und Jugendpsychiatrie_765	Kothgassner Oswald
UE76506002	Digitale Gesundheitsanwendung in der Kinder- und Jugendpsychiatrie-Phase I	Kinder- und Jugendpsychiatrie_765	Kothgassner Oswald
FA729A0158	A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (disease caused by infection with severe acute respiratory syndrome coronavirus-2)	Klinische Pharmakologie_729	Jilma Bernd

FA729A0168	A Two-Period, Randomised, Cross-over Study in Healthy Subjects to investigate the pharmacokinetic and pharmacodynamic equivalence and safety of two different recombinant tPA presentations (PBS-tPA versus Actilyse®), at low and high subtherapeutic doses in the ascending part of the dose-response curve	Klinische Pharmakologie_729	Jilma Bernd
FA729A0266	A Phase 1/2, Randomized, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD9550 in Overweight and Obese Participants with Type 2 Diabetes Mellitus	Klinische Pharmakologie_729	Wolzt Michael
FA729A0741	Comparison of the performance and safety of T2769 versus Vismed Multi in the treatment of moderate to severe Dry Eye Syndrome	Klinische Pharmakologie_729	Garhöfer Gerhard
FA729A0742	The effect of systemic hypoxia on retinal tissue oxygen saturation in healthy subjects - a pilot study	Klinische Pharmakologie_729	Garhöfer Gerhard
FA729A1105	An open-label, Single-arm, Multicenter Phase 1b study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with sHLH; Project Code: 35041	Klinische Pharmakologie_729	Schörghofer Christian
FA729A1401	JPND - PET analyses of ABC transporter function for diagnostics and stratification of dementia patients (PETABC)	Klinische Pharmakologie_729	Langer Claus Oliver
FA729A1404	Quantitative evaluation of the brain distribution and pharmacokinetics of isavuconazole using positron emission tomography (PET) imaging	Klinische Pharmakologie_729	Langer Claus Oliver

FA729A1802	In vitro hydrolysis of Landiolol and Esmolol in whole blood of healthy volunteers	Klinische Pharmakologie_729	Nussbaumer-Pröll Alina
FA729A1901	Blood donation to investigate ex vivo blood activation in a hemodialysis circuit	Klinische Pharmakologie_729	Miljevic Katarina
FA729A2001	Safety and immunogenicity of concomitant administration of the Novavax vaccine and a 20-valent-pneumococcal conjugate vaccine in adults aged > 60 years: a four-arm, double-blind, non-inferiority trial	Klinische Pharmakologie_729	Jorda Anselm
FA729A2101	Assessing the tissue pharmacokinetics of [11C]rezafungin in healthy volunteers with positron emission tomography (PET) imaging	Klinische Pharmakologie_729	Mairinger Severin
FA794C0404	Multicenter Study on the Prevalence and Genomic Properties of Carbapenemaseproducing Pseudomonas aeruginosa in Austria Hospitals	Krankenhaushygiene und Infektionskontrolle_794	Diab-El Schahawi Magda
FA712A0708	Untersuchungen gesundheitlicher Auswirkungen und der zugrunde liegenden molekularen Mechanismen durch einen gallussäurehaltigen Pflanzenextrakt	Krebsforschung_712	Knasmüller Siegfried
FA712A0913	Trax&Viels-03: Validation of the Xpert® Insight Breast Cancer test to stratify outcomes in premenopausal women with hormone receptor positive, HER2-negative early breast cancer and evaluation of the concordance of Xpert® Breast Cancer STRAT4 with IHC assessment of routine breast cancer biomarkers (ER, PgR, HER2 and Ki67) – a retrospective translational study of biomarker cohort ABCSG-12	Krebsforschung_712	Filipits Martin
FA712A0914	ABCSG TR Artera: Digitale Histopathologie - multimodale künstliche Intelligenz für eine maßgeschneiderte Prognose und	Krebsforschung_712	Filipits Martin

	Behandlungsauswahl bei Frauen mit Brustkrebs		
FA712A1002	Fibrose-Multiplex-ELISA	Krebsforschung_712	Mikulits Wolfgang
FA712A2002	Unraveling the dark matter of infectious diseases, environmental and genetic factors tipping the balance towards NCDs	Krebsforschung_712	Vogl Thomas
FW712A0201	CAFs and Albumin-targeting drugs	Krebsforschung_712	Adamova Barbora
FA793A0327	071102 rVWF in Pediatrics	Labormedizin_793	Quehenberger Peter
FA793A0807	Modulation von oxidativem Stress bei Stoffwechselerkrankungen	Labormedizin_793	Binder Christoph
FA793A0808	Oxitope Thrombosis	Labormedizin_793	Binder Christoph
FA793A0809	Investigating the effects of Trimodulin in Coagulation and Thrombosis	Labormedizin_793	Binder Christoph
FA793A1903	Human Mental Performance - Der Einfluss von Cortisol als Stressmarker bei militärischen Spezialeinsatzkräften im operativen Bereich	Labormedizin_793	Haslacher Helmuth
FA793A1906	BBMRI.at Phase 3	Labormedizin_793	Haslacher Helmuth
FA793A1907	Blutausstriche und Knochenmark-Ausstriche Analyse: Leistungsbewertung Vision Pro	Labormedizin_793	Haslacher Helmuth
FA793A2001	Development of therapeutics targeting mutant CALR	Labormedizin_793	Kralovics Robert
FA793A2102	checkit!	Labormedizin_793	Luf Anton
FA793A2701	Kooperation Looplabbio cAMP in T cells	Labormedizin_793	Schmetterer Klaus
FA793A2801	Exploiting organoid model systems to explore systemic conditions worsening COVID19: merging cellular and genetic engineering	Labormedizin_793	Penninger Josef
FA793A2802	Swedish Research Council	Labormedizin_793	Penninger Josef
FA793B0122	Nachweis von Galactomannan	Labormedizin_793	Willinger Birgit
FA793B0123	Study on the in vitro activity of Cefiderocol against gram-negative pathogens isolated from cystic fibrosis patients as part of routine diagnostics in the years 2015-2023	Labormedizin_793	Willinger Birgit

FA793C0205	A mono-center, retrospective clinical study with residual archived samples to evaluate the performance of the NeuMoDx™ HIV-1 Quant Assay on the NeuMoDx systems (for IVDR)	Labormedizin_793	Straßl Robert Paul
FA793C0206	A monocenter, retrospective clinical study with residual archived samples to evaluate the performance of the NeuMoDx HBV Quant Assay on the NeuMoDx systems (for IVDR)	Labormedizin_793	Straßl Robert Paul
FW793A0101	Sialoproteome driven immune response in breast cancer	Labormedizin_793	Mereiter Stefan
FA602A0122	LS23-Leitprojekt: Smart and Federated Open data eXchange of citizen-based data donations for clinical research	Medical Data Science_303	Stamm Tanja
FA632A0207	EU HORIZON Sharing and re-using clinical trial data to maximise impact	Medical Data Science_303	Posch Martin
FA632A0208	Innovative designs, extrapolation, simulation methods and evidence-tools for rare diseases addressing regulatory needs	Medical Data Science_303	Posch Martin
FA660A1106	statistische Analyse des „Multicenter randomized controlled COTTIS-2 trial“	Medical Data Science_303	Heinze Georg
FA660A1207	Entwicklung und datenbasierte Evaluation klimafreundlicher Maßnahmen zur Minderung hitzebedingter Gesundheitsrisiken	Medical Data Science_303	Klimek Peter
FW632A0101	FWF 32Methods for complex trial designs with shared controls	Medical Data Science_303	Bofill Roig Marta
FA632A0607	Analyse und Bewertung der Ernährungssituation und Qualität der Ernährungsversorgung in Krankenhäusern und in stationären Altenpflegeeinrichtungen	Medical Data Science_303	Hiesmayr Jörg Michael
FA632A0606	Does the ERAS program implementation change the rate of nutrition therapy use? A nutritionDay analysis 2006-2023	Medical Data Science_303	Hiesmayr Jörg Michael
CD10260504	Schalllabor für die Entwicklung der nächsten Generation von Ultraschallgeräten	Medizinische Physik und Biomedizinische Technik_340	Figl Michael

FA605A0410	Handheld optical coherence tomography	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
FA605A0705	Research-Neural-Interfaces Multikontaktelektrode für präklinische Versuche zur Verifizierung der Langezeitstabilität der Multikontaktelektrode	Medizinische Physik und Biomedizinische Technik_340	Lanmüller Hermann
FA605A1006	Hochauflösender Biosignalverstärker	Medizinische Physik und Biomedizinische Technik_340	Bijak Manfred
FA605A1905	Ink-Based Hybrid Multi-Material Fabrication Of Next Generation Implants	Medizinische Physik und Biomedizinische Technik_340	Moscato Francesco
FA605A2002	Ultraschall-Translationsinvarianz für Bildgütephantome	Medizinische Physik und Biomedizinische Technik_340	Hummel Johann
FA605A2301	Coating of Neurovascular Stents	Medizinische Physik und Biomedizinische Technik_340	Grasl Christian
FA605A2501	Point-of-care instrument for diagnosis and image-guided intervention of Colo-Rectal Cancer	Medizinische Physik und Biomedizinische Technik_340	Unterhuber Angelika
FA605A3001	Rb-PET-PRC: Positron range correction for cardiac Rubidium PET	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
UE60506007	Future SS-OCT technologies, High speed OCT, functional OCT and Synthetic aperture imaging OCT	Medizinische Physik und Biomedizinische Technik_340	Drexler Wolfgang
UE60506010	CDG-Internship im CD Labor für Modellierung und Simulation von neuen Ultraschallgeräten	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA602A0114	The mental Health eXperience; Indication - iNtervention - eXperience	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA602A0117	EUROSTARS-2 CoD13: 114332 RB4.0 - Develop a digital service to improve care and quality of life in patients with Rheumatoid Arthritis	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA602A0117	EUROSTARS-2 CoD13: 114332 RB4.0 - Develop a digital service to improve care and quality of life in patients with Rheumatoid Arthritis	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA602A0118	COTIDIANA_2 - Mobile Patient-centred System to Improve Drug	Medizinische Statistik, Informatik	Stamm Tanja

	Trials and Care of Older-adults with Rheumatic Diseases	und Intelligente Systeme_303	
FA602A0118	COTIDIANA_2 - Mobile Patient-centred System to Improve Drug Trials and Care of Older-adults with Rheumatic Diseases	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA632A0206	EU Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy, EJP RD	Medizinische Statistik, Informatik und Intelligente Systeme_303	Posch Martin
FA632A0604	29000nutritionDay	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael
FA660A0708	Emotional Well-Being in the Digital Society	Medizinische Statistik, Informatik und Intelligente Systeme_303	Metzler Hannah
FA660A0805	Implementation for the Action "European Health Data & Evidence Network"	Medizinische Statistik, Informatik und Intelligente Systeme_303	Dufts Schmid Georg
FA660A1104	Statistische Beratung und Feedback bei Studien zu den Themen Digital Health, Big Data und Patientensicherheit - LBI-DHPS	Medizinische Statistik, Informatik und Intelligente Systeme_303	Heinze Georg
FA660A1105	Neuentwicklung eines Cardiac-Allocation-Scores (CAS)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Heinze Georg
UE63206001	Verein ASDI - Zertifizierung von Intensivstationen	Medizinische Statistik, Informatik und Intelligente Systeme_303	Graf Alexandra
FA736A0504	Gehirnflüssigkeiten neurochirurgischer Patienten zur Expansion von Immunzellen	Neurochirurgie_736	Widhalm Georg
FA736A0704	Hämoglobin in der Zerebrospinalflüssigkeit (Liquor) für das Monitoring von sekundären Hirnschäden nach aneurysmatischer Subarachnoidalblutung - eine prospektive multinationale Validierungsstudie (HeMoVal-Studie)	Neurochirurgie_736	Rössler Karl

FA736A0801	Evaluation of Sutability of Cold Ablation Robot Guided Laser Osteotomy for Stereoelectroencephalography (SEEG) Surgical Procedures in Sheep	Neurochirurgie_736	Rössler Karl
FW736A0101	Receptor-ligand synergies between medulloblastoma cell types	Neurochirurgie_736	Gabler Lisa
FA761A1125	The effect of Cladribine on iron rims around lesions, lesion expansion, brain atrophy and disease progression in multiple sclerosis patients - an observational exploratory study	Neurologie_761	Berger Thomas
FA761A1135	The epidemiology and clinical characterisation of 5q-linked spinal muscular atrophy in Austria	Neurologie_761	Berger Thomas
FA761A1160	A multicenter, randomized, open-label, adaptive phase I study to investigate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ascending intravenous doses of Glofitamab, administered after Ocrelizumab pretreatment, in patients with multiple sclerosis	Neurologie_761	Berger Thomas
FA761A1161	A multicenter, prospective, non-interventional study to determine the cutoff and clinical performance of the Elecsys(R) Amyloid Plasma Panel and its component assays	Neurologie_761	Berger Thomas
FA761A1162	A randomized, double-blind, parallel-group, acitve controlled trial with open-label safety extension to evaluate the tolerability, safety and efficacy of Atogepant versus Topiramate in subjects requiring preventive treatment of Migraine (TEMPLE)	Neurologie_761	Berger Thomas
FA761A1163	A phase 4, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of Rimegepant for the prevention of migraine in adults	Neurologie_761	Berger Thomas

	with a history of inadequate response to oral preventive medications		
FA761A1164	A phase 4, randomized, doubleblind, placebo-controlled, efficacy and tolerability trial of Rimegepant for the acute treatment of migraine in adults unsuitable for Triptan use	Neurologie_761	Berger Thomas
FA761A1201	Establishment of a data- and biobank of patients with VPS35 mutations	Neurologie_761	Zimprich Alexander
FA796A0117	Joint Action on integration of ERNs into national healthcare systems	Neurologie_761	Voigtlaender Till
FA796A0701	Histologie	Neurologie_761	Amberg Nicole
FA796A0702	Nanopore sequencing	Neurologie_761	Amberg Nicole
FA796A0703	Nanopore sequencing	Neurologie_761	Amberg Nicole
FA796A0704	Nanopore sequencing	Neurologie_761	Amberg Nicole
FA796A0801	Systematic study of IgG4-autoimmune diseases to develop new treatment strategies	Neurologie_761	Koneczny Inga
FW761A0102	Targeting Neuroinflammation in Friedreich's Ataxia	Neurologie_761	Berger Thomas
FA761A1110	An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis	Neurologie-Klinik_761	Berger Thomas
FA728A1203	„Clinical Performance of Elecsys® Troponin T hs Gen 6 in Subjects with Symptoms of Acute Coronary Syndrome – PERFORM-TSIX Study – Study No. CIM RD005477“	Notfallmedizin_728	Niederdöckl Jan
FA728A1303	Digitalisierung medizinischen Wissens als Basis für intelligente Lösungen für die Hämato-Onkologie und Notfallmedizin	Notfallmedizin_728	Roth Dominik
FA728A1501	Förderung weiterer Arbeit Forschungsgruppe Dr. Schnaubelt	Notfallmedizin_728	Schnaubelt Sebastian
FA728A1502	The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary	Notfallmedizin_728	Schnaubelt Sebastian

	intervention- A prospective, randomized, double-blinded, placebo-controlled, phase IV pilot trial (STEMILAND-1)		
FA737A0616	EU H2020-SC1-2017-Single-Stage-RTD/Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain	Orthopädie und Unfallchirurgie_739	Windhager Reinhard
FA737A0622	SOLARIO - Short or Long Antibiotic Regimes In Orthopaedics	Orthopädie und Unfallchirurgie_739	Windhager Reinhard
FA737A1801	Einfluss der autologen Transplantatwahl und der Operationstechnik zur Rekonstruktion des vorderen Kreuzbands auf die postoperative Muskelaktivität gemessen mittels Tensiomyographie - eine prospektive, randomisierte Studie	Orthopädie und Unfallchirurgie_739	Koller Ulrich
FA737A1801	Einfluss der autologen Transplantatwahl und der Operationstechnik zur Rekonstruktion des vorderen Kreuzbands auf die postoperative Muskelaktivität gemessen mittels Tensiomyographie - eine prospektive, randomisierte Studie	Orthopädie und Unfallchirurgie_739	Koller Ulrich
FA737A2002	Fixierung von Densfrakturen Typ II mittels eines Allograft-Osteosynthesystems	Orthopädie und Unfallchirurgie_739	Benca Emir
FA737B0101	B1: Cartilage for Cartilage regeneration: Laser engraved decellularized cartilage as biomaterial for defect treatment	Orthopädie und Unfallchirurgie_739	Nürnberger Sylvia
FA737B0201	In-vivo Testung einer magnesiumbasierten, intramedullären Spannosteosynthese im Kaninchenmodell	Orthopädie und Unfallchirurgie_739	Hajdu Stefan
FA608A0329	TBI-5	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA681A0206	Role of Matrix Metalloproteinase-12 in a mouse model of sarcoidosis	Pathobiochemie und Genetik_306	Weichhart Thomas
FA681A0210	A Mouse Model Study to Evaluate Granuloma Formation in the Lung	Pathobiochemie und Genetik_306	Weichhart Thomas

FA791A0723	SOPHiA aims to develop a bundle solution product (BS) composed of an analytical algorithm and an associated capture kit, to assess Homologous Recombination repair Deficiency (HRD) score using targeted sequencing on HR genes with low pass WGS to calculate HRD score, including to be used to classify tumour suitability for PARP inhibitor or platinum based chemotherapy treatment.	Pathologie_791	Müllauer Leonhard
FA791A1031	Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	Pathologie_791	Kain Renate
FA791A1032	A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (AVANZAR)	Pathologie_791	Kain Renate
FA791A1033	A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial)	Pathologie_791	Kain Renate
FA791A1135	Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-	Pathologie_791	Simonitsch-Klupp Ingrid

	Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy		
FA791A1154	R-Pola-Glo - A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R CHOP	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1155	A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1156	“A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma”	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1157	An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B Cell Lymphoma (ZUMA-23)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1649	„ Validation of the Xpert® Insight Breast Cancer test to stratify outcomes in Pre-menopausal Women with Hormone Receptor positive (HR+), HER2-negative early breast cancer and Evaluation of the Concordance of Xpert® Breast Cancer STRAT4 with IHC assessment of routine breast cancer biomarkers (ER, PgR, HER2	Pathologie_791	Bago-Horvath Zsuzsanna

	and Ki67) - a retrospective translational study of biomarker cohort ABCSG-12“(„TraX&Vields-03“)		
FA791A1650	A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1651	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1652	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1653	A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy	Pathologie_791	Bago-Horvath Zsuzsanna

FA791A1654	A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1655	CAMBRIA-1: „A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence”	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1656	„ Validation of the Xpert® Insight Breast Cancer test to stratify outcomes in Pre-menopausal Women with Hormone Receptor positive (HR+), HER2-negative early breast cancer and Evaluation of the Concordance of Xpert® Breast Cancer STRAT4 with IHC assessment of routine breast cancer biomarkers (ER, PgR, HER2 and Ki67) - a retrospective translational study of biomarker cohort ABCSG-12“(„TraX&Vields-03“	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A3411	“A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors”	Pathologie_791	Comperat Eva Maria

FA791A3901	A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients.	Pathologie_791	Kozakowski Nicolas
FA623A0220	INDUCTION OF HBV VIRUS NEUTRALIZING ANTIBODIES IN HEALTHY VACCINE NAIVE ADULTS AND NON-RESPONDERS AND IN PATIENTS CHRONICALLY INFECTED WITH HBV USING VVXX001	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann- Schmidt Ursula
FA623A0225	Adjuvanted allergen molecules for Treatment and prevention of allergy	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann- Schmidt Ursula
FA623A0801	Vector-borne diseases in den Einsatzgebieten des Österreichischen Bundesheeres: Kosovo und Bosnien und Herzegowina (BIH)	Pathophysiologie, Infektiologie und Immunologie_370	Kniha Edwin
FA624A0215	In vitro immunogenicity assays I	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA624A0216	Generation and Evaluation of KRAS specific TCRs	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA624A0217	Evaluation of mRNA vaccine designs using TCR-transgenic reporter cell lines	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA644A0511	Evaluierung innovativer molekularer Analyseverfahren und -ansätze zur Überwachung von Antibiotikaresistenzen im Abwasser	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander
FA644A0802	Airfilter Monitoring	Pathophysiologie, Infektiologie und Immunologie_370	Bergthaler Andreas
FA644A0803	Abwassermonitoring als Instrument der Krisenprävention, sowie des Krisen- und Pandemiemanagements	Pathophysiologie, Infektiologie und Immunologie_370	Bergthaler Andreas
FA644A0901	Pathogen surveillance through wastewater in Gabon	Pathophysiologie, Infektiologie und Immunologie_370	Amman Fabian

FA648A0310	The library of allergenic molecules	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0316	Allergen profiling of asthma subjects within the LEAD Study	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0317	Development of allergen microarray silicon chips	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0317	Development of allergen microarray silicon chips	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0617	Development of seed-derived nutraceuticals for the treatment of obesity and related disorders and its combined effects with a high intensity interval training protocol (NUTRISEEDDEX)	Pathophysiologie, Infektiologie und Immunologie_370	Pietschmann Peter
FA648A0618	Unterstützung der Errichtung und Betreuung eines Editorial Office für die Wiener Medizinische Wochenschrift und der Publikationstätigkeit der Arbeitsgruppe für Knochenforschung	Pathophysiologie, Infektiologie und Immunologie_370	Pietschmann Peter
FA648A0809	Allergios II - Analysis of allergen-induced degranulation of basophil cells	Pathophysiologie, Infektiologie und Immunologie_370	Breiteneder Heimo
FA648A1709	Evaluierung des Zusammenhangs zwischen dem chronischem Erschöpfungssyndrom und Immundefizienzen mit Auswirkung auf die mukosale Barrierefunktionen	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A1711	The impact of allergen-immunotherapy (AIT) formulations on immunogenicity and efficacy of AIT in a murine model	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A1712	Praxisleitfäden für eine ME/CFS-orientierte Primärversorgungs-Einrichtung	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A1712	Praxisleitfäden für eine ME/CFS-orientierte Primärversorgungs-Einrichtung	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva

FA648A1713	ME/CFS Biobank Austria	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A1903	DARC (Danube Allergy Research Cluster) - Towards Cure of Allergy, Teilprojekt #03: "Towards Cure and Prevention of Birch Pollen-Related Food Allergy".	Pathophysiologie, Infektiologie und Immunologie_370	Bohle Barbara
FA648A1903	DARC (Danube Allergy Research Cluster) - Towards Cure of Allergy, Teilprojekt #03: "Towards Cure and Prevention of Birch Pollen-Related Food Allergy".	Pathophysiologie, Infektiologie und Immunologie_370	Bohle Barbara
FA648A2004	EU Innovative ligands for nuclear receptors to eradicate cancer relapse.	Pathophysiologie, Infektiologie und Immunologie_370	Schepelmann Martin
FA648A2303	Systems Biology and Spatial Transcriptomics for unlocking the germinal center biology	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakova Diana
FA649A0201	Austrian Lyme Disease Laboratory Survey and Sentinel Surveillance	Pathophysiologie, Infektiologie und Immunologie_370	Schmid Daniela
FW644A0101	Clusters of Excellence	Pathophysiologie, Infektiologie und Immunologie_370	Bergthaler Andreas
UE62306001	Observational Study on the Clinical Use of EVUSHELD (AZD7442) in Austria	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA624A0602	Projekt F0999906864 Immunzellen Analyse	Pathophysiologie, Infektiologie und Immunologie_370	Boucheron Nicole
FA624A0601	Projekt F0999906863 Immunzellen Analyse	Pathophysiologie, Infektiologie und Immunologie_370	Boucheron Nicole
FA726A0502	Evaluierung Josefhof - Programm "Gesunder Rücken"	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726	Crevenna Richard
FA621A0601	Zusammenarbeitsvereinbarung "Apeiron Biologics AG"	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA641A0117	Aktivierung von Gs-gekoppelte EP2- Rezeptoren	Physiologie und Pharmakologie_350	Zebedin-Brandl Eva Maria
FA641A0120	SCLC-BET2 Amendment No.3	Physiologie und Pharmakologie_350	Hamilton Gerhard
FA641A0120	SCLC-BET2 Amendment No.3	Physiologie und Pharmakologie_350	Hamilton Gerhard

FA641A0605	Toxicology assays for polyoxometalates	Physiologie und Pharmakologie_350	Sitte Harald
FA641A0606	Selektive OCT3 Inhibitoren	Physiologie und Pharmakologie_350	Sitte Harald
FA641A1201	NEUROtransmitter TRANSPorters: from single molecules to human pathologies (Neuro Trans)	Physiologie und Pharmakologie_350	Stockner Thomas
FW625A0101	Crosstalk between PI3K Signalling & SIGN-R1 in Autoimmunity	Physiologie und Pharmakologie_350	Hromadova Dominika
FA763B1201	Eine randomisierte, doppelblinde, placebokontrollierte Phase III Studie zur Untersuchung der Wirksamkeit und Sicherheit von BI 425809 bei einer einmal täglichen Gabe über einen Behandlungszeitraum von 26 Wochen bei Patienten mit Schizophrenie (CONNEX-3)	Psychiatrie und Psychotherapie_763	Rujescu-Balcu Dan
FA763C0207	Verringerung der Folgen von übermäßigem Alkoholgenuss	Psychiatrie und Psychotherapie_763	Wancata Johannes
FA763C0801	VOICE – Patient Involvement in Individuals with lived experience of Clinical High Risk for Psychosis	Psychiatrie und Psychotherapie_763	Hinterbuchinger Barbara
FA638A0302	Assoziation des Gesundheitsstatus bei der Stellung und Mortalität bei österreichischen Stellungspflichtigen- eine retrospektive, explorative Studie"	Public Health_380	Waldhör Thomas
FA638A0404	Preventing obesity through biologically and behaviorally tailored interventions for you	Public Health_380	Schernhammer Eva
FA646A0705	INTERACT Europe 100	Public Health_380	Grabovac Igor
FA646A0804	Lebensmittelwerbung an Kinder und die Wirksamkeit der Selbstkontrolle	Public Health_380	Winzer Eva
FA646A1102	Gesund fürs Leben	Public Health_380	Haider Sandra
FA646A1201	ACE Casino	Public Health_380	Fischer Gabriele
FA646A1202	ASW Wetten	Public Health_380	Fischer Gabriele
FA646A1301	MigraCare - Einbindung von 24-Stunden-Betreuer:innen in Pflegenetzwerke in Österreich	Public Health_380	Wojczewski Silvia
FA646A1301	MigraCare - Einbindung von 24-Stunden-Betreuer:innen in Pflegenetzwerke in Österreich	Public Health_380	Wojczewski Silvia
FA647A0116	Air Pollution in Kosovo - impact on human health, behaviour change and policy recommendations	Public Health_380	Moshammer Hanns

FA647A0117	Future Capacity - Social vulnerability and adaptive capacity to risks from the impacts of future heat waves and air pollution	Public Health_380	Moshammer Hanns
FA647A0518	Effekte hoch- und niederfrequenter elektromagnetischer Felder unter Berücksichtigung von Kombinationswirkungen mit krebserzeugenden Arbeitsstoffen - NIRMES	Public Health_380	Hutter Hans-Peter
FA647A0801	New Options for Resilient Measures for human health and well-being in the construction industry under climate change in Austria	Public Health_380	Haluza Daniela
FA647A0804	Making Green Inclusive. Ecosystem Services, Health Impact Assessment and Participative Scenarios	Public Health_380	Haluza Daniela
FA669A0113	Aripiprazole/ sertraline combination: Clinical and cost-effectiveness in comparison with quetiapine for the treatment of bipolar depression. An open label randomised controlled trial. (ASCEnD)	Public Health_380	Simon Judit
FA669A0201	Schätzung und Verlauf der sozioökonomischen Heterogenität in der Lebensspanne auf Basis von VN-Todesanzeigen in Vorarlberg (1946-1981)	Public Health_380	Mayer Susanne
UE64606004	Nahda University of Beni Suef (NUB)	Public Health_380	Rieder Anita
UE64606004	Nahda University of Beni Suef (NUB)	Public Health_380	Rieder Anita
CD10277102	CD-Labors für Nicht invasive Tumorcharakterisierung	Radiologie und Nuklearmedizin_771	Haug Alexander
FA771B0421	A Phase 2a, Randomized, Placebo-controlled, double-blind study to assess the safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn's Disease	Radiologie und Nuklearmedizin_771	Helbich Thomas

FA771B0422	a randomized, open-label, phase 3 Trial to compare the efficacy and safety of idecabtagene vicleucel with lenalidomide maintenance vs lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation (KarMMa-9) (CA089-1043)	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B0883	AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B0893	A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (Pvd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide ("Clinical Study")	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B1309	Ultra Low dose CT for follow-up examinations in patients with progressive pulmonary fibrosis – a prospective pilot study	Radiologie und Nuklearmedizin_771	Prosch Helmut

FA771B1310	A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients with Idiopathic Pulmonary Fibrosis	Radiologie und Nuklearmedizin_771	Prosch Helmut
FA771B1605	Can Contrast-Enhanced Mammography (CEM) replace Contrast-Enhanced Breast Magnetic Resonance Imaging (bMRI) in the assessment of equivocal breast findings? An intra-individual comparison	Radiologie und Nuklearmedizin_771	Baltzer Pascal
FA771E0316	Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients with Anaplastic Astrocytoma or Glioblastoma: Phase IB Study	Radiologie und Nuklearmedizin_771	Kasprian Gregor
FA771E0510	Medical Imaging - Praktika für Schüler/innen 2023	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E0511	Projekt KI in der Radiologie um nutzerorientierte Strategie für den Zukünftigen Einsatz von künstlicher Intelligenz in den praktischen Arbeitsabläufe.	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E0709	Aufbau einer Datenbank manueller Segmentierungen von Knorpel des Knies zur Evaluierung eines Algorithmus zur automatischen Segmentierung des Knorpels im Knie	Radiologie und Nuklearmedizin_771	Trattinig Siegfried
FA771E0803	1000-Ideen TAI 676-N	Radiologie und Nuklearmedizin_771	Bogner Wolfgang
FA771E0805	Deuterium labeling of GLUCOSE improves magnetic resonance imaging Sensitivity to CANcer metabolism	Radiologie und Nuklearmedizin_771	Bogner Wolfgang
FA771E1602	A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients >_12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von	Radiologie und Nuklearmedizin_771	Kasprian Gregor

	Willebrand Factor-XTENfusion proteinfor 24 months		
FA771G0245	B1: Dynamic column-based 3D cell culture method for drug and radiotracer evaluation	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0259	Combination therapy in combating cholangiocarcinoma	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0270	Testung von einem FAP-Affilin in der IHC	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0276	“Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD) I8F-MC-GPIG	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0277	“A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors”	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0278	Project: 101080327-Lightcure-HORIZON-HLTH-2022-DISEASE-06-two stage	Radiologie und Nuklearmedizin_771	Kulterer Oana Cristina
FA771G0280	Eine multizentrische, prospektive, nicht-interventionelle Studie zur Bestimmung des Cut-off-Werts der klinischen Leistung des Elecsys Amyloid Plasma Panel und seiner Komponenten-Assays.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FW771E0101	Platform for brain research using UHG MRI, histology and AI	Radiologie und Nuklearmedizin_771	Bogner Wolfgang
FA771G0275	MTA RayzeBio MTA and CA9 radiolabeling	Radiologie und Nuklearmedizin_771	Hacker Marcus

FA771B0892	A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy” to, Protocol 64007957MMY3005	Radiologie und Nuklearmedizin_771	Herold Christian
CD10277402	CD-Labor für Bild- und erkenntnisbasierte Präzisionsstrahlentherapie	Radioonkologie_774	Knäusl Barbara
FA774A0204	“Tailored Axillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized open labeled phase III trial” (“Studie”)	Radioonkologie_774	Kauer-Dorner Daniela
FA774A0502	Technische Funktionalität und Design vom ETD Prototyp	Radioonkologie_774	Lechner Wolfgang
FA774A0503	Korrelation von Oberflächendaten mit X-Ray Daten (Phantombehandlung)	Radioonkologie_774	Lechner Wolfgang
FA774A1401	Artificial Intelligence Driven online Adaptive radiotherapy (AIDA)	Radioonkologie_774	Trnkova Petra
FA774A0802	A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)	Strahlentherapie_774	Altorjai Gabriela
FA774A1101	Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRachytherapy in locally advanced Cervical cancer – EMBRACE.	Strahlentherapie_774	Kirisits Christian

AP23033MWF	Einstellung zu assistiertem Suizid, aktiver, indirekter und passiver Sterbehilfe: Eine Repräsentativbefragung bei der österreichischen Allgemeinbevölkerung	Teaching Center_302	Holzinger Anita
FA731T0101	Europäisches IPF Netzwerk: Neue pathomechanistische Erkenntnisse und innovative therapeutische Perspektiven.	Thoraxchirurgie_733	Hötzenecker Konrad
FA731T0506	Viral load guided Immunosuppression after Lung Transplantation An open-label, randomized, controlled, parallel-group, multicenter trial	Thoraxchirurgie_733	Jaksch Peter
FA733A0202	ECP therapy to prevent CLAD in patients with persistent de novo DSA - EU Project exTRA 101119855	Thoraxchirurgie_733	Benazzo Alberto
FA733A0303	Austrosheld - Observational Study on the Clinical Use of Evusheld in immunocompromised patients (AZD7442) in Austria	Thoraxchirurgie_733	Jaksch Peter
FA733A0402	AC1804: Untersuchung der Wirkung von Arzneimitteln in malignen Pleuraergüssen und Aszites: eine Pilotstudie	Thoraxchirurgie_733	Hoda Mir Ali Reza
FA733A0501	Identification of subtype-specific biomarkers in small cell lung cancer	Thoraxchirurgie_733	Dome Balazs
FA727A0620	Herstellung APN401 für die APN401-104 Studie	Transfusionsmedizin und Zelltherapie_727	Worel Nina
FA727A0803	An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B Cell Lymphoma (ZUMA-23)	Transfusionsmedizin und Zelltherapie_727	Müller Antonia Maria Susanne
FA727A0804	A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (Zuma 25)	Transfusionsmedizin und Zelltherapie_727	Müller Antonia Maria Susanne

FA727A0805	A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9) (CA089-1043)	Transfusionsmedizin und Zelltherapie_727	Müller Antonia Maria Susanne
FA727A0806	MAP, JOIN AND DRIVE EUROPEAN ACTIVITIES FOR ADVANCED THERAPY MEDICINAL PRODUCT DEVELOPMENT AND IMPLEMENTATION FOR THE BENEFIT OF PATIENTS AND SOCIETY (JOIN4ATMP)	Transfusionsmedizin und Zelltherapie_727	Müller Antonia Maria Susanne
FA670A0103	"Vergleich der Genauigkeit digitaler versus konventioneller Implantat-getragener Kronenversorgungen: eine klinische Studie"	Universitätszahnklinik_670	Schedle Andreas
FA670A0108	Erstellen von Kriterien zur Beurteilung der Qualität von Kompositmaterialien und der Langlebigkeit von Kompositfüllungen	Universitätszahnklinik_670	Schedle Andreas
FA670F0301	Initial adhesion and proliferation of gingival fibroblasts on dental implants	Universitätszahnklinik_670	Andrukhov Oleh
FA670F0302	Zellen aus Zähnen	Universitätszahnklinik_670	Andrukhov Oleh
FA670F0501	Investigation of biomechanical effects of Eruption Guidance Appliance (EGA) on the jaw bones and temporomandibular joints	Universitätszahnklinik_670	Sagl Benedikt
FA670F0601	Adaptierung und Optimierung von histologischen Färbemethoden um Spezifität der Gewebeklassifizierung zu verbessern	Universitätszahnklinik_670	Tangl Stefan
FA743A0227	A randomized, double-blind, placebo-controlled phase 2 study to evaluate the testicular safety of filgotinib in adult males with	Urologie_743	Shariat Shahrokh

	moderately to severely active ulcerative colitis		
FA743A0236	Eine randomisierte, doppelblinde Studie der Phase III zu Pembrolizumab (MK-3475) plus Docetaxel plus Prednison versus Placebo plus Docetaxel plus Prednison bei Teilnehmern mit einem nicht mit Chemotherapie vorbehandelten metastasierendem kastrationsresistentem Prostatakarzinom (Metastatic Castration-Resistant Prostate Cancer, mCRPC), bei denen während der Behandlung mit einem hormonellen Wirkstoff der nächsten Generation (Next Generation Hormonal Agent, NHA) eine Krankheitsprogression eingetreten ist	Urologie_743	Shariat Shahrokh
FA743A0237	Eine Phase-III-Studie zu Erdafitinib im Vergleich mit Vinflunin oder Docetaxel oder Pembrolizumab bei Patienten mit fortgeschrittenem Urothelkarzinom und ausgewählten FGFR-Gen-Aberrationen	Urologie_743	Shariat Shahrokh
FA743A0239	A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of a PSMA bispecific T-cell Engager (BiTE) AMG 160 in Subjects with Metastatic Castration Resistant Prostate Cancer (mCRPC)	Urologie_743	Shariat Shahrokh
FA743A0240	Characterization of the PARP Inhibitor Talazoparib as Novel Therapeutic Option in Advanced Bladder Cancer	Urologie_743	Shariat Shahrokh
FA743A0244	Eine einarmige, multizentrische, internationale prospektive Studie zur Bewertung der Wirksamkeit des vorübergehend implantierbaren Medizinprodukts der Firma Medi-Tate (iTind) bei	Urologie_743	Shariat Shahrokh

	Patienten mit benigner Prostatahyperplasie (BPH).		
FA743A0252	A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors	Urologie_743	Shariat Shahrokh
FA743A0253	A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Clear-Cell Variant Renal Cell Carcinoma Who Progressed After 1st Line Treatment with Checkpoint Inhibitors	Urologie_743	Shariat Shahrokh
FA743A0254	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Urologie_743	Shariat Shahrokh
FA743A0256	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Urologie_743	Shariat Shahrokh
FA743A0270	Dosisescalations- und Erweiterungsstudie zur Sicherheit und Wirksamkeit von XL092 in Kombination mit immunonkologischen Wirkstoffen bei Patienten mit inoperablen fortgeschrittenen oder metastasierten soliden Tumoren.	Urologie_743	Shariat Shahrokh
FA743A0271	First line randomized study platform to optimize treatment in	Urologie_743	Shariat Shahrokh

	patients with metastatic renal cell carcinoma		
FA690A0402	TBE in Austria - Extended assessment of clinical course including sequelae and vaccination status of virologically verified TBE cases based on active surveillance	Virologie_307	Aberle Judith

Markus Müller

Rektor